Compare ProShares Ultra Silver ETF (AGQ) vs ARK Genomic Revolution ETF (ARKG) Price & Performance

AGQ, a leveraged silver ETF, trades at $81.11, down 0.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights volatility, with articles noting a 9.39% surge on silver rallies but structural decay risks from daily-reset leverage. Financial ratios are unavailable as AGQ is an ETF tracking silver futures, not a company with fundamentals.

The outlook hinges on silver price momentum, offering amplified gains but high risk from leverage decay and silver volatility. Key risks include underperformance versus unlevered ETFs and sharp declines during silver sell-offs, as seen in a 16% drop in June 2026. Investors should weigh silver's bullish trend against ETF-specific drawbacks.

ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.

Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.